RA
SGMO

Rise Advisors’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Rise Advisors’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-853
Closed -$574 – 1197
2025
Q3 		$574 Buy
+853
New +$460 ﹤0.01% 1380

Other funds holding SGMO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Rise Advisors's SGMO Position: Q4 2025 in Review

Rise Advisors sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2025, closing a stake of 853 shares — an estimated $574 sold.

Rise Advisors first reported a position in SGMO in Q3 2025 and held it in 1 quarter. The position peaked at $574 in Q3 2025. 105 funds tracked by Wall St. Rank hold SGMO as of Q4 2025.

  • Rise Advisors reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2025 after selling out during the quarter.
  • Rise Advisors sold 853 SANGAMO THERAPEUTICS INC shares in Q4 2025, an estimated $574.
  • Rise Advisors first reported a position in SANGAMO THERAPEUTICS INC in Q3 2025 and held it in 1 quarter.
  • Rise Advisors's SANGAMO THERAPEUTICS INC position peaked at $574 in Q3 2025.
  • 105 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2025.

Based on Rise Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.